In its new Sunnyvale, Texas location, GenesisCare offers comprehensive patient-centered services for patients with breast cancer.
Sunnyvale, Texas, January 20, 2022 – GenesisCare—one of the leading oncology providers in the United States, Australia, Spain, and the United Kingdom—today announced the opening of its new Sunnyvale Women's Center with patient-friendly facilities and an experienced clinical team to this new site to provide Dallas-area residents with end-to-end, multidisciplinary breast healthcare. The comprehensive patient-centered services available include mammography, diagnosis, treatment, and post-treatment follow-up. Patients will have rapid access to advanced and innovative technologies that deliver unprecedented accuracy, faster treatment sessions, and a reduced risk of side effects.
On average, one-in-eight American women (13%)1 will develop breast cancer in their lifetime. In 2022, we will see approximately 287,8502 new cases of invasive breast cancer, along with 51,400 new non-invasive (in situ) breast cancer.
The American Cancer Society ranked Texas as the second state in the nation for having the highest number of cases per capita, with an estimated 20,900 new cases of female breast cancer with 3,420 deaths in 2021.
"The Sunnyvale Women's Center allows us to meet the need for effective, targeted diagnosis and treatment with easy, local access," shares Dr. Anita Tharian, DO, GenesisCare
Medical Oncologist. "Bridging gaps in care is especially important as regular women's screening and care being disrupted by COVID across the Dallas area."
Two-time cancer survivor and GenesisCare patient Brenda George shares, "My experiences with GenesisCare have been truly phenomenal. I began receiving treatment immediately after being diagnosed, which helped me improve my chances of fighting my cancer. My oncologist, Dr. Tharian, made my recovery her top priority."
Dr. Tharian adds, "Offering access to advanced precision medicine, like DCISionRT, has proven to help patients and doctors make informed decisions about their care. Combined with other leading technologies like AlignRT, we are also able to lower the risk of heart damage in radiation treatment for breast cancer."
The women's center's world-leading diagnostic tools and treatments use various advanced technologies to streamline the process and deliver patients' best possible life outcomes.
Innovative tools include:
AlignRT®—a surface-guided radiation therapy—provides unprecedented accuracy
and efficiency using 3-D cameras, so it pauses at the slightest movement.
DCISionRT® -delivers the most advanced Ductal Carcinoma in Situ (DCIS) test
available by looking at the biology of an individual's specific cancer using a
molecular assessment to predict risk and guide treatment plans for better outcomes.
Hologic®'s 3D mammography -new 3DimensionsTMsystem provides a more
comfortable mammography experience and higher-quality 3D images for
radiologists to find invasive cancers regardless of age or breast density.
Hologic®'s DXA system—the latest in densitometry technology—measures bone density and has a complete fracture risk assessment.
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
November 13th 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Apalutamide Outperforms Enzalutamide in mCSPC Survival
November 8th 2024In an interview with Targeted Oncology, Neal Shore, MD, FACS, discussed the background, findings, and implications of a real-world study of enzalutamide and apalutamide in patients with metastatic castration-sensitive prostate cancer.
Read More